UBS Group
ENGN icon

UBS Group’s enGene Therapeutics ENGN Stock Holding History

UBS Group’s Portfolio ENGN Stock Details ENGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$88.6K Buy
13,017
+11,420
+715% +$102K ﹤0.01% 7057
2025
Q4 		$14.4K Buy
+1,597
New +$12.8K ﹤0.01% 8004
2025
Q2 		– Sell
-1,200
Closed -$5.38K – 10387
2025
Q1 		$5.38K Hold
1,200
– – ﹤0.01% 9004
2024
Q4 		$7.98K Buy
+1,200
New +$9.32K ﹤0.01% 8436
2024
Q3 		– Sell
-3,370
Closed -$31.8K – 9632
2024
Q2 		$31.8K Buy
+3,370
New +$43.2K ﹤0.01% 7024
2024
Q1 		– Sell
-1,937
Closed -$17.9K – 9474
2023
Q4 		$17.9K Buy
+1,937
New +$17.1K ﹤0.01% 7173

Other funds holding ENGN

FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

UBS Group's ENGN Position: Q1 2026 in Review

UBS Group increased its enGene Therapeutics (ENGN) stake by 715% in Q1 2026, buying an estimated $102K and bringing the position to 13,017 shares worth $88.6K. The position accounts for ﹤0.01% of the portfolio, ranked #7057.

UBS Group first reported a position in ENGN in Q4 2023 and has held it in 6 quarters since. 61 funds tracked by Wall St. Rank hold ENGN as of Q1 2026.

  • UBS Group held 13,017 shares of enGene Therapeutics worth $88.6K as of Q1 2026.
  • UBS Group bought 11,420 enGene Therapeutics shares in Q1 2026, an estimated $102K.
  • enGene Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #7057 holding.
  • UBS Group first reported a position in enGene Therapeutics in Q4 2023 and has held it in 6 quarters since.
  • 61 funds tracked by Wall St. Rank held enGene Therapeutics as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.